scholarly journals Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline

2016 ◽  
Vol 27 (3) ◽  
pp. 264-267 ◽  
Author(s):  
Marco Maruzzo ◽  
Antonella Brunello ◽  
Alberto Diminutto ◽  
Marco Rastrelli ◽  
Umberto Basso
Keyword(s):  
Female Patient ◽  
First Line ◽  
Elderly Female ◽  
Term Response

scholarly journals 87-year-old woman with improved pulmonary function following accidental long-term inhalation therapy with dabigatran

2018 ◽  
pp. bcr-2018-225566
Author(s):  
Volker Pönitz ◽  
Karl Jakob Evensen
Keyword(s):  
Pulmonary Function ◽  
Lung Disease ◽  
Female Patient ◽  
Dabigatran Etexilate ◽  
Inhalation Therapy ◽  
Serum Concentrations ◽  
Restrictive Lung Disease ◽  
Elderly Female

Accidental long-term dabigatran etexilate inhalation was associated with subtherapeutic dabigatran serum concentrations in an elderly female patient with restrictive lung disease. A significant improvement in her pulmonary function was noted without other therapy directed towards her bronchopulmonary disease.

Long-term response in metastatic renal cell carcinoma patients receiving first-line therapy with VEGF TKIs.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 436-436
Author(s):  
Srinivas Kiran Tantravahi ◽  
Shiven B. Patel ◽  
Sowmya Ravulapati ◽  
Julia A. Batten ◽  
Joseph Merriman ◽  
...  
Keyword(s):  
Renal Cell ◽  
Clinical Characteristics ◽  
Progression Free Survival ◽  
Categorical Variables ◽  
Survival Outcomes ◽  
First Line ◽  
Chi Square ◽  
First Line Therapy ◽  
Term Response

436 Background: A subset of metatstatic renal cell carcincoma (mRCC) patients (pts) on first-line (1st) vascular endothelial growth factor inhibitors (VEGF TKIs) will have a long-term response (LTR) defined as a progression free survival (PFS) of >18 months (mos) on continuous therapy, and may be candidates for intermittent VEGF TKI therapy. Methods: From our institutional dataset of mRCC pts, we identified pts receiving 1st VEGF TKIs and who achieved a LTR. Data on clinical characteristics and survival outcomes were compared between those with LTRs and rest of the patients (control). Continuous and categorical variables were assessed by Wilcoxon rank sum and chi-square, respectively; and survival outcomes were compared by log-rank tests. Results: Of 89 pts, 24 (33%) had LTRs, of whom 5 pts have discontinued treatment (range 1-5 years) without subsequent disease progression, and 4 pts took treatment breaks for 3-9 mos. Baseline pts or disease characteristics were not predictive of LTRs (Table). Conclusions: A subset of mRCC pts receiving 1st VEGF TKIs achieve a LTR, and are not currently identifiable by baseline clinical characteristics including prognostic risk categorization. Identification of biomarkers predictive of LTR may allow intermittent or even deferred therapy with VEGF TKIs minimizing toxicity and cost. [Table: see text]

scholarly journals P3.01-026 Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC

2017 ◽  
Vol 12 (11) ◽  
pp. S2210
Author(s):  
M. Schuler ◽  
J.C. Yang ◽  
L. Sequist ◽  
Y. Wu ◽  
C. Zhou ◽  
...  
Keyword(s):  
First Line ◽  
Term Response

scholarly journals A Case with Atypical Clinical Course Diagnosed as Osteoarthritis, Osteonecrosis, Subchondral Insufficiency Fracture, or Rapidly Destructive Coxopathy

2014 ◽  
Vol 8 (1) ◽  
pp. 20-23 ◽  
Author(s):  
Yukio Nakamura ◽  
Mikio Kamimura ◽  
Keijiro Mukaiyama ◽  
Shota Ikegami ◽  
Shigeharu Uchiyama ◽  
...  
Keyword(s):  
Female Patient ◽  
Clinical Course ◽  
Insufficiency Fracture ◽  
Imaging Evaluation ◽  
Subchondral Insufficiency Fracture ◽  
Radiographic Diagnosis ◽  
Elderly Female ◽  
Long Term Follow Up

Osteonecrosis (ON), subchondral insufficiency fracture (SIF), and rapidly destructive coxopathy (RDC) are considered to be clinically different disorders despite exhibiting several overlapping features. We encountered an elderly female patient with an atypical clinical course who was radiographically diagnosed as having osteoarthritis (OA), ON, SIF, and/or RDC over a long-term follow-up. In this case, radiographic diagnosis was apparently affected by the timing of imaging evaluation and was challenging because of radiographic overlap and atypical disease progression. The disorders of OA, SIF, ON, and RDC might share a similar pathophysiology.

scholarly journals Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study

2018 ◽  
Vol Volume 11 ◽  
pp. 5845-5852 ◽  
Author(s):  
Andrés Redondo ◽  
Manuel Ramos Vázquez ◽  
Luis Manso ◽  
Miguel J Gil Gil ◽  
Isabel Garau Llinas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
First Line ◽  
Term Response

scholarly journals Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience

2018 ◽  
Vol 38 (8) ◽  
pp. 4913-4918 ◽  
Author(s):  
ANDREA SBRANA ◽  
ELISA BIASCO ◽  
FEDERICO PAOLIERI ◽  
ERICA PALESANDRO ◽  
CLAUDIA CASERTA ◽  
...  
Keyword(s):  
First Line ◽  
Italian Experience ◽  
Term Response

Long-term responders to everolimus: A subgroup analysis of the sector study.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 462-462
Author(s):  
Philippe Barthelemy ◽  
Bernard Escudier ◽  
Florence Joly ◽  
Lionnel Geoffrois ◽  
Brigitte Laguerre ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Predictive Factors ◽  
Subgroup Analysis ◽  
Prolonged Treatment ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Biological Studies ◽  
Term Response

462 Background: Everolimus is considered as a standard of care for the second line treatment of metastatic renal cell carcinoma (mRCC). Currently no clinical or biological predictive factors are available to help physicians to choose the best second line option between everolimus or TKI. Whether correlation exists between response to first line and response to second line remains debatable. Methods: We performed a subgroup analysis of the SECTOR study, a retrospective survey of patients (pts) receiving everolimus after TKI in 26 french centers to analyse long responders to everolimus. Long-term response to everolimus was defined as progression-free >9 months. Recorded variables included: patients characteristics of first line TKI (duration, response), duration of everolimus, efficacy and toxicity as well as overall survival. Results: 164 patients in 26 french cancer centres were included in the SECTOR study between october 2008 and october 2012. All patients received everolimus as second line treatment. Median age was 64.6 y.o, main histological subtype was clear-cell carcinoma (92.3%). Among the whole study cohort, we identified 30 patients (21%) as long-term responders (ranging from 9 to 33 months). Analysis of this patient population is ongoing and will be presented at the meeting. Correlation between long response and prognostic factors, as well as response to first TKI will be determined. Conclusions: Everolimus achieves long-term response in more than 20% of mRCC treated in second line. Prolonged treatment was relatively well tolerated without any unexpected late toxicity. Further investigations, especially biological studies, are warranted to identify predictive factors which will help physicians to identify long-term responder and choose the best second line option for mRCC patients.

Long-Term Sustained Disease Control With Immunotherapy in Chemotherapy-Refractory Merkel Cell Carcinoma

2019 ◽  
pp. 8-11
Author(s):  
Deborah Yihler ◽  
Kathrin Vollmer ◽  
Antonio Cozzio
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Inadequate Response ◽  
Merkel Cell ◽  
First Line ◽  
Treatment Protocols ◽  
First Line Therapy ◽  
Significant Toxicity ◽  
Clinical Responses

ABSTRACT Merkel cell carcinoma (MCC) is a rare and difficult-to-treat cutaneous malignancy with a poor prognosis. Treatment protocols for localized MCC are well established. Until recently, metastatic MCC has generally been treated with chemotherapy, which was often associated with poor clinical responses and significant toxicity. In this report, the case of a patient with metastatic MCC who received avelumab, an immune checkpoint inhibitor, after an inadequate response to first-line radiotherapy and chemotherapy, is presented. Nine months after the initiation of the treatment with avelumab, the patient achieved a partial remission with no treatment-related adverse events. After a follow-up of 17 months, a systematically ongoing partial response was reported. In conclusion, this case study offers a clinical insight into the patient’s case and highlights the importance of immunotherapy as a first-line therapy for metastatic MCC.

scholarly journals Erythema Gyratum Repens in Long-Term Smoker

2019 ◽  
Vol 11 (3) ◽  
pp. 268-272
Author(s):  
Andrew P. Sauvageau ◽  
Jacob Mojeski ◽  
Thomas W. Fiorica ◽  
Craig C. Miller
Keyword(s):  
Female Patient ◽  
Skin Condition ◽  
Morbidity And Mortality ◽  
Cancer Growth ◽  
Internal Malignancy ◽  
Adenocarcinoma Of The Lung

Erythema gyratum repens (EGR) is a rare paraneoplastic skin condition characterized by the eruption of expanding, concentric, erythematous patches and plaques. The condition may precede a symptomatic appearance of internal malignancy, and therefore provides a unique opportunity to prevent additional morbidity and mortality secondary to undetectable cancer growth. We report the case of a 71-year-old female patient clinically diagnosed with EGR and subsequently diagnosed with otherwise asymptomatic adenocarcinoma of the lung.

Sign in / Sign up

Export Citation Format

Share Document